2 to 1
Atomoxetine, brand name, Strattera, was approved by the FDA for distribution in November 2002
10 Since its initial approval in the US, ATX has been marketed in approximately 90 countries and is widely used, accounting for 6% of prescriptions written for ADHD treatment visits in the US in
1%, and in adults, it ranges between 3% and 5%
This drug is more popular than comparable drugs
Medscape - Attention deficit hyperactivity disorder (ADHD)-specific dosing for Strattera (atomoxetine), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information
fatigue (low energy) appetite loss
1
pelvic pain in male
4% (5/1357 patients), compared to none in placebo-treated patients (851 patients)
Stimulants increase brain levels of the neurotransmitters dopamine and norepinephrine, which are linked to focus and attention
The typical Strattera dosage for children ages 6 to 17 depends on their weight
It is the first non-stimulant medication approved for the treatment of ADHD
Atomoxetine is subsidised on the Pharmaceutical Benefits